Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumour growth

BMC Cancer

Volumn 2, Issue , 2002, Pages

  Lefesvre, Pierre ^a   Attema, Joline ^a   van Bekkum, Dirk ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOSTATIN; APROTININ; CHIMERIC PROTEIN; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; METALLOPROTEINASE INHIBITOR; PLASMIN INHIBITOR; THALIDOMIDE; UROKINASE RECEPTOR; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; CELL SURFACE RECEPTOR; COLLAGEN; HYBRID PROTEIN; PEPTIDE FRAGMENT; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; SERINE PROTEINASE INHIBITOR; UROKINASE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GENETIC CODE; GENETIC TRANSDUCTION; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG SQUAMOUS CELL CARCINOMA; MALE; NONHUMAN; RAT; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; ADENOVIRUS; ANIMAL; BROWN NORWAY RAT; CANCER TRANSPLANTATION; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; GENE TRANSFER; GENE VECTOR; GENETICS; INTRALESIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG CARCINOMA; LUNG TUMOR; METABOLISM; METASTASIS; METHODOLOGY; RAT STRAIN; VASCULARIZATION;

ADENOVIRIDAE; ANGIOGENESIS INHIBITORS; ANIMALS; APROTININ; CARCINOMA, BRONCHOGENIC; COLLAGEN; DRUG DELIVERY SYSTEMS; ENDOSTATINS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; RATS; RATS, INBRED BN; RATS, INBRED STRAINS; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; SERINE PROTEINASE INHIBITORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 3042755194     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-2-17     Document Type: Article

References (42)

1. Li CY, Shan S, Huang Q, Braun RD, Lanzen J, Hu K, Lin P, Dewhirst MW: Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 2000, 92:143-147
2. Miyake H, Hara I, Yamanaka K, Arakawa S, Kamidono S: Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J Oncol 1999, 14:535-541
3. Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E, Nenci GG: Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer 1996, 77:1079-1088
4. Skelly MM, Troy A, Duffy MJ, Mulcahy HE, Duggan C, Connell TG, O'Dono ghue DP, Sheahan K: Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin Cancer Res 1997, 3:1837-1840
5. van der Burg ME, Henzen-Logmans SC, Berns EM, van Putten WL, Klijn JG, Foekens JA: Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int J Cancer 1996, 69:475-479
6. Ito H, Yonemura Y, Fujita H, Tsuchihara K, Kawamura T, Nojima N, Fujimura T, Nose H, Endo Y, Sasaki T: Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. Virchows Arch 1996, 427:487-496
7. Zhang X, Fei Z, Bu X, Zhen H, Zhang Z, Gu J, Chen Y: Expression and significance of urokinase type plasminogen activator gene in human brain gliomas. J Surg Oncol 2000, 74:90-94
8. Takanami I, Takeuchi K, Karuke M: Expression of ETS-1 is correlated with urokinase-type plasminogen activator and poor prognosis in pulmonary adenocarcinoma. Tumour Biol 2001, 22:205-210
9. de Vries TJ, Quax PH, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, Weidle UH, Ruiter DJ, van Muijen GN: Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994, 144:70-81
10. He CS, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, Goldberg GI: Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci U S A 1989, 86:2632-2636
11. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P: Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. Embo J 1997, 16:2319-2332
12. Pyke C, Kristensen P, Ralfkiaer E, Grondahl-Hansen J, Eriksen J, Blasi F, Dano K: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991, 138:1059-1067
13. Estreicher A, Muhlhauser J, Carpentier JL, Orci L, Vassalli JD: The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990, 111:783-792
14. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA: Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997, 100:58-67
15. Rifkin DB, Moscatelli D, Bizik J, Quarto N, Blei F, Dennis P, Flaumenhaft R, Mignatti P: Growth factor control of extracellular proteolysis. Cell Differ Dev 1990, 32:313-318
16. Bacharach E, Itin A, Keshet E: In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc Natl Acad Sci U S A 1992, 89:10686-10690
17. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM: Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992, 119:629-641
18. Li H, Lu H, Griscelli F, Opolon P, Sun LQ, Ragot T, Legrand Y, Belin D, Soria J, Soria C, Perricaudet M, Yeh P: Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther 1998, 5:1105-1113
19. Li H, Griscelli F, Lindenmeyer F, Opolon P, Sun LQ, Connault E, Soria J, Soria C, Perricaudet M, Yeh P, Lu H: Systemic delivery of antiangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice. Hum Gene Ther 1999, 10:3045-3053
20. Belin D, Vassalli JD, Combepine C, Godeau F, Nagamine Y, Reich E, Kocher HP, Duvoisin RM: Cloning, nucleotide sequencing and expression of cDNAs encoding mouse urokinase-type plasminogen activator. Eur J Biochem 1985, 148:225-232
21. Lamfers ML, Lardenoye JH, de Vries MR, Aalders MC, Engelse MA, Grimbergen JM, van Hinsbergh VW, Quax PH: In vivo suppression of restenosis in balloon-injured rat carotid artery by adenovirus-mediated gene transfer of the cell surface-directed plasmin inhibitor ATF.BPTI. Gene Ther 2001, 8:534-541
22. Lage A, Diaz JW, Gonzalez I: Effect of proteinase inhibitor in experimental tumors. Neoplasma 1978, 25:257-259
23. Gavilondo J, Perez R, Mainardi V, Lage A: Effect of two antiproteinases on the growth of transplantable tumors and the proliferation of untransformed and transformed cells in culture. Neoplasma 1982, 29:315-322
24. Latner AL, Longstaff E, Turner GA: Anti-tumour activity of aprotinin. Br J Cancer 1974, 30:60-67
25. Dhanabal M, Ramchandran R, Volk R, Stillman IE, Lombardo M, Iruela-Arispe ML, Simons M, Sukhatme VP: Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 1999, 59:189-197
26. Read TA, Sorensen DR, Mahesparan R, Enger PO, Timpl R, Olsen BR, Hjelstuen MH, Haraldseth O, Bjerkvig R: Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol 2001, 19:29-34
27. Sorensen DR, Read TA, Porwol T, Olsen BR, Timpl R, Sasaki T, Iversen PO, Benestad HB, Sim BK, Bjerkvig R: Endostatin reduces vascularization, blood flow, and growth in a rat gliosarcoma. Neuro-oncol 2002, 4:1-8
28. Peroulis I, Jonas N, Saleh M: Antiangiogenic activity of endostatin inhibits c6 glioma growth. Int J Cancer 2002, 97:839-845
29. Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G, Menard S, Gatter KC, Harris AL, Fox S, Buyse M, Pilotti S, Pierotti M, Rilke F: Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 1997, 151:1417-1423
30. Landuyt W, Verdoes O, Darius DO, Drijkoningen M, Nuyts S, Theys J, Stockx L, Wynendaele W, Fowler JF, Maleux G, Van den Bogaert W, Anne J, van Oosterom A, Lambin P: Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer 2000, 36:1833-1843
31. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, Fogler WE, Sim BK, Allred EN, Pirie-Shepherd SR, Folkman J: Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001, 61:7669-7674
32. Kim Lee Sim B, Fogler WE, Zhou XH, Liang H, Madsen JW, Luu K, O'Reilly MS, Tomaszewski JE, Fortier AH: Zinc ligand-disrupted recombinant human Endostatin: Potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 1999, 3:41-51
33. Koopman JL, Slomp J, de Bart AC, Quax PH, Verheijen JH: Mitogenic effects of urokinase on melanoma cells are independent of high affinity binding to the urokinase receptor. J Biol Chem 1998, 273:33267-33272
34. Esandi MC, Verlinden SFF, Vries de MW, Pfeffer G, Bekkum van DW: Neutralizing antibodies against Adeno 5 virus open the therapeutic window for interleukin-3 gene therapy of tumors with adenovirus 5 based vectors. submitted to gene therapy 2001
35. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D, Hoeben RC: New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998, 9:1909-1917
36. Fallaux FJ, Kranenburg O, Cramer SJ, Houweling A, Van Ormondt H, Hoeben RC, Van Der Eb AJ: Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996, 7:215-222
37. Shabram PW, Giroux DD, Goudreau AM, Gregory RJ, Horn MT, Huyghe BG, Liu X, Nunnally MH, Sugarman BJ, Sutjipto S: Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther 1997, 8:453-465
38. Kal HB, Zurcher C, van Bekkum DW: Induction of lung tumors by radioactive isotopes implanted in the rat lung. J Natl Cancer Inst 1986, 76:943-946
39. Kal HB, Meijnders PJ, Van Berkel AH, Van Bekkum DW: Response to chemotherapy of non-small cell bronchial rat tumours growing subcutaneously or in the lung. In Vivo 1991, 5:301-306
40. Marquet RL, Westbroek DL, Jeekel J: Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. Int J Cancer 1984, 33:689-692
41. Esandi MC, van Someren GD, Bout A, Mulder AH, van Bekkum DW, Valerio D, Noteboom JL: IL-1/IL-3 gene therapy of non-small cell lung cancer (NSCLC) in rats using 'cracked' adenoproducer cells. Gene Ther 1998, 5:778-788
42. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254